Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9415904 | 0.83 | L3MBTL1 (0.35) | L3MBTL1MAPK1ALDH1A1TP53CYP3A4 | |
| SCHEMBL9644015 | 0.82 | L3MBTL1 (0.38) | L3MBTL1MAPK1ALDH1A1TP53CYP3A4 | |
| SCHEMBL9644012 | 0.81 | L3MBTL1 (0.38) | L3MBTL1MAPK1ALDH1A1TP53CYP3A4 | |
| SCHEMBL22490151 | 0.81 | L3MBTL1 (0.34) | L3MBTL1MAPK1ALDH1A1 | |
| SCHEMBL17717878 | 0.81 | L3MBTL1 (0.34) | L3MBTL1MAPK1ALDH1A1 | |
| SCHEMBL29329710 | 0.80 | SMN1; SMN2 (0.36) | L3MBTL1MAPK1ALDH1A1TP53CYP3A4 | |
| SCHEMBL21781851 | 0.80 | L3MBTL1 (0.41) | L3MBTL1MAPK1ALDH1A1TP53CYP3A4 | |
| SCHEMBL1952351 | 0.80 | SMN1; SMN2 (0.36) | L3MBTL1MAPK1ALDH1A1TP53CYP3A4 | |
| SCHEMBL16591121 | 0.80 | LMNA (0.33) | L3MBTL1MAPK1ALDH1A1CYP3A4 | |
| SCHEMBL21301194 | 0.79 | LMNA (0.44) | L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160164057-A1 | ELECTROCHEMICAL CELL WITH POLYIMIDE SEPARATOR AND HIGH-VOLTAGE POSITIVE ELECTRODE | SOLVAY SA (BE) | 2016-06-09 | — | — | US | disclosed |
| US-8735005-B2 | Fluorinated cyclic carbonates and compositions thereof | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-05-27 | — | — | US | disclosed |
| US-20110244313-A1 | Fluorinated Cyclic Carbonates and Compositions Thereof | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110244313-A1 | Fluorinated Cyclic Carbonates and Compositions Thereof | CA2, PFAS, CA7 | L3MBTL1 4814/4885MAPK1 870/4885ALDH1A1 3770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.